**Short Communication** 

# Efficacy of D-penicillamine Challenge Test for Diagnosis of Wilson Disease

Norikazu Shimizu, Atsuko Watanabe, Junko Nakazato, Hiroaki Nakamura, Misako Inoue, Kaoru Hirai and Tsugutoshi Aoki

Second Department of Pediatrics, Toho University School of Medicine, Tokyo 153-8515, Japan

## Abstract

Wilson disease is an autosomal recessive disorder of copper metabolism characterized by hepatic and/or neurological manifestations. This biochemical features of this disease are low serum ceruloplamine levels and high urinary copper excretion. Early diagnosis is very important to improve the prognosis of this disease. However, some patients revealed atypical biochemical findings. This study presents the efficacy of D-penicillamine challenge test for diagnosis of Wilson disease. Five patients and five normal controls were loaded 20mg/kg of D-penicillamine. Urinary copper / body weight (kg) ratio and/or urinary copper / creatinine ratio showed significant difference between Wilson disease patients and controls. The D-penicillamine challenge test will be useful for diagnosis of Wilson disease.

Keywords: Wilson disease, inborn error of copper metabolism, D-penicillamine, D-penicillamine challenge test, urinary copper excretion

#### Introduction

Wilson disease is an autosomal recessive disorder based on inborn error of copper metabolism. Copper is accumulated primarily in the liver, brain, cornea, kidney, and other organs. The copper accumulation is believed to result from the loss of ability to excrete copper via the bile due to a dysfunction of intracellular copper transport in the liver. The Wilson disease gene (ATP7B) encodes a putative copper-transporting P-type ATPase. Clinical features of this disease are liver cirrhosis, extra pyramidal signs and Kayser-Fleischer ring. The incidence is one in 35,000 to 45,000 in Japan<sup>1)</sup>. Low serum ceruloplas-

Address correspondence to :

Norikazu Shimizu

Second Department of Pediatrics

Toho University, School of Medicine,

2-17-6, Ohashi, Meguro,

Tokyo 153-8515, Japan

TEL: 03-3468-1251

FAX: 03-3468-2927

E-mail: norikazu@med.toho-u.ac.jp

Received: 7 September 2007 Revised: 12 October 2007 Accepted: 13 October 2007 mine level, low serum copper level and high urinary copper excretion are typical biochemical findings of this disease. Diagnostic criteria of Wilson disease is based on these biochemical features<sup>2</sup>. However, some patients with Wilson disease show atypical biochemical findings, such as normal serum ceruloplasmine levels and/or low urinary copper excretion.

In this study, the authors report the efficacy of Dpenicillamine challenge test for diagnosis of Wilson disease.

# Subjects and Methods

1) Wilson disease patients

Five patients with Wilson disease, 6, 7, 8, 12 and 18 years old, were investigated. All of them were hepatic type of Wilson disease, and were newly diagnosed.

#### 2) Normal controls

Three healthy volunteers (adult) cooperated with this study. And two children (12 and 15 years old) were used as normal controls. Although they were suspected with Wilson disease due to liver dysfunction and were performed D-penicillamine challenge test, Wilson disease was denied by another workup.

# 3) D-penicillamine challenge


- a) Wilson disease patients
  - D-penicillamine was started 5-10 mg/kg/day and was increased to maintenance dose, step by step. And when they took 20 mg/kg/day of D-penicillamine, urinary copper levels were measured.
- b) Normal controls

Twenty milligram per kilogram of D-penicillamine was taken for one day.


- c) D-penicillamine was given 2 or 3 times per day at least 1 hour before or 2 hours after meals.
- 4) Measurement of urinary copper excretion Daily urinary copper levels and urinary creatinine levels were measured. Then urinary copper / body weight (kg) ratio and urinary copper / creatinine ratio were calculated.

## Results


1) Daily urinary copper excretion during D-



**Fig. 1** Daily urinary copper excretion during D-panicillamine challenge test Lane 1 to 5 are Wilson disease patients, lane 1 is 6-year-old, 2 is 7-year-old, 3 is 8-year-old, 4 is 12-year-old and 6 is 18-year old. Lane 6 to 10 are normal controls, lane 6 is 12-year-old, 7 is 15-year-old and 8 to 10 are adult.



**Fig. 2** Urinary copper / body weight ratio during D-panicillamine challenge test Distributions of each lane are same as figure 1.



**Fig. 3** Urinary copper / creatinine ratio during D-panicillamine challenge test Distributions of each lane are same as figure 1.

penicillamine challenge test

The daily urinary copper excretion of Wilson disease patients was 852.0 to  $6291.2~\mu g/day$  and one of normal controls was 709.0 to  $2080.0~\mu g/day$  (Fig. 1). There is no significant difference between patients and controls.

- 2) Urinary copper / body weight ratio
  Urinary copper / body weight (kg) ratio of Wilson disease patients was 48.69 to 96.86 μg/kg/day
  (72.52 ± 19.20 μg/kg/day) and one of normal controls was 13.38 to 32.62 μg/kg/day (23.60 ± 6.70 μg/kg/day) (Fig.2). It was significant greater in patients with Wilson disease compared to controls.
- 3) Urinary copper / creatinine ratio
  Urinary copper / creatinine ratio of Wilson disease
  patients was 2.27 to 4.86 μg/mg creatinine (3.55±
  0.78 μg/mg creatinine) and one of normal controls
  was 0.45 to 1.32 μg/mg creatinine (0.86±0.25 μg/
  mg creatinine) (Fig.3). It was significantly higher in
  Wilson disease patients than in controls.

## Discussion

The diagnostic criteria of Wilson disease are low serum ceruloplasmine levels (20 mg/dl>) and high urinary copper excretion (100 µg/day<, 1.5 µg/kg< or 0.2 µg/mg creatinine<)<sup>2)</sup>. However, some patients show atypical biochemical findings. The limitation of biochemical tests have been reported in several studies<sup>3),4)</sup>. Although measurement of hepatic copper content is still considered the golden standard<sup>3)</sup>, liver biopsy is invasive inspection. The diagnostic value of D-penicillamine challenge test was

discounted by several authorities and different cut-off levels have been proposed<sup>4) 5)</sup>. In previous studies, 1000 mg of D-penicillamine was ingested and cut-off level was established as  $1600 \, \mu g/day^{4) \, 6)$ . Although this protocol is a valuable diagnostic test for the symptomatic Wilson disease child, it is not effective for presymptomatic patients and adult patients<sup>4)</sup>.

In this study, 20 mg/kg/day of D-penicillamine was ingested for various ages of patients with Wilson disease and controls. One Wilson disease patient did not reach previously established cut-off value of 1600 mg/day and two normal controls reached it (Fig. 1). Daily urinary copper excretions followed by D-penicillamine challenge test were not significantly different between Wilson disease patients and normal controls (Fig. 1). Thus, this cutoff value may not help for diagnose of Wilson disease. However, urinary copper / body weight (kg) ratio and urinary copper / creatinine ratio of Wilson disease patients were significantly higher than normal controls (Fig. 2 & 3). D-penicillamine challenge test using these ratios will be useful as non-invasive testing for Wilson disease. Urinary copper / creatinine ratio must be measured for spot urine samples. If yes, this test can be performed for out-patients. It may be convenient for patients. The authors would like to propose temporary cut-off value of 35 µg/kg/day and/or 2.0 µg/mg creatinine for Dpenicillamine 20 mg/kg/day challenge test. In the future, many and variable kinds of Wilson disease patients (especially for asymptomatic type patients) and control subjects (for example another live disease) should be investigated. Then, the efficacy of our protocol must be confirmed and final cut-off value should be established.

#### References

- 1) Aoki T et al: Nationwide survey of clinical feature of Wilson's disease in Japan. Lam STS, Pang CCP (eds): Neonatal and Perinatal Screening, the Asian pacific perspective, The Chinese University Press, Hong Kong, 1996, p25-28.
- 2) Fujii H: Ceruloplasmin and copper metabolism in presymptomatic patients with Wilson's disease, establishment of diagnostic criteria. Biomed Res Trace Elements 8: 13-21, 1997 (in Japanese)
- 3) Roberts EA, Schilsky ML: A practice guideline on Wilson disease. Hepatology 37: 1475-1492, 2003

- 4) Muller T, Koppikar S, Taylor RM, Carragher F, Schlenck B, Heinz-Erian P, Kronenberg F, Ferenci P, Tanner S, Siebert U, Staudinger R, Mieli-Vergani G, Dhawan A: Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. J Hepatol 47: 270-276, 2007
- 5) Sternlieb I: Perspectives on Wilson's disease. Hepatology 12: 1234-1239, 1990
- 6) Martins da Costa C, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli-Vergani G: Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology 15: 609-615, 1992